Press

I’m Living the Life I Was Destined to Have

Reaching for the Right to Live: David Hysong

SHEPHERD Therapeutics and Mayo Clinic Announce Collaboration to Advance Research in Rhabdomyosarcoma Using SHEPHERD's Precision-Oncology Platform, DELVE

SHEPHERD Therapeutics Announces Research Collaboration with National Institutes of Health's (NIH) National Center for Advancing Translational Sciences (NCATS) in Adenoid Cystic Carcinoma (ACC)

SHEPHERD Therapeutics and Oncoheroes Biosciences to Partner for the Discovery, Development and Commercialization of Oncology Therapeutics For Rare Cancers

30 Under 30 Spotlight: Unsung Heroes in Healthcare David Hysong | Forbes Healthcare Summit 2019

I Lost My Son to a Rare Cancer. I Don't Want Others to Go Through the Same Pain.

“Repurposing” off-patent drugs offers big hopes of new treatments

David Hysong and SHEPHERD Therapeutics

Top 20 Life Science Startups to Watch in 2018

Idealism in Action

A 29-year-old founded a biotech startup to cure rare cancers after he got a life-changing diagnosis

Searching for a Cure

Ford Profile: David Hysong

Publications

Identification of Transcriptional Plasticity Biomarkers for Patient Stratification

Toward Imrpoved Cancer Classification

Using PCS + tSNE Dimensionality Reduction on Bulk RNA-sq Data

Closing the Target Gap

A Computational Approach to Optimizing Therapeutic Selection for Cancer Patients

Transcriptome-Driven Combination Design

A Computational Approach